Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 7291 to 7305 of 7963 results

  1. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued [GID-TA10298]

  2. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued [GID-TA10306]

  3. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued [GID-TA10308]

  4. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

  5. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued [GID-TA10310]

  6. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued [GID-TA10315]

  7. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued [GID-TA10318]

  8. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued [GID-TA10320]

  9. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued [GID-TA10321]

  10. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued [GID-TA10322]

  11. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

  12. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued [GID-TA10325]

  13. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued [GID-TA10327]

  14. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued [GID-TA10329]

  15. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued [GID-TA10330]